EYS and glaucoma: It is likely that this limited the GWAS to detect only exceedingly frequent founder mutations in EYS. However, increasing the number of cases and controls should greatly facilitate detection of less frequent founder mutations as demonstrated in recent large-scale GWAS studies that have boosted the number of disease-associated loci from a few initially to often dozens including those for glaucoma and age-related macular degeneration21,39,40.